Skip to main content
SpringerLink
Log in

Integrating “Omics” Data for Quantitative and Systems Pharmacology in Translational Oncology

  • Chapter
  • First Online:
Micro and Nano Flow Systems for Bioanalysis

Part of the book series: Bioanalysis ((BIOANALYSIS,volume 2))

Abstract

Cancer is the phenotypic end point of multiple genetic aberrations and epigenetic modifications that have accumulated within its genome. These genetic and epigenetic alterations come together to form complex, dynamic, and plastic networks that govern the “hallmarks of cancer.” The development of new technologies and powerful computational algorithms to sequence and characterize genomes have enabled researchers to acquire and analyze measurement of tens of thousands of “omic” data points across these genetic and epigenetic changes within cancer genomes. Quantitative and Systems Pharmacology (QSP) represents one of these translational medicine approaches that integrates computational and experimental methods to elucidate, validate, and apply new pharmacological concepts to the development and use of small molecule and biologic drugs. QSP is a promising approach that can provide a scientifically rational approach for defining optimal multidrug regimens, identifying responsive patient populations, identifying translational biomarkers, and designing clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Agoram BM, Demin O (2011) Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development. Drug Discov Today 16:1031–1036

    Article  Google Scholar 

  2. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J et al (2011) Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333:1154–1157

    Article  Google Scholar 

  3. Allerheiligen SR (2010) Next-generation model-based drug discovery and development: quantitative and systems pharmacology. Clin Pharmacol Ther 88:135–137

    Article  Google Scholar 

  4. Bassingthwaighte J, Hunter P, Noble D (2009) The cardiac physiome: perspectives for the future. Exp Physiol 94:597–605

    Article  Google Scholar 

  5. Bassingthwaighte JB, Raymond GM, Butterworth E, Alessio A, Caldwell JH (2010) Multiscale modeling of metabolism, flows, and exchanges in heterogeneous organs. Ann N Y Acad Sci 1188:111–120

    Article  Google Scholar 

  6. Beyer A, Bandyopadhyay S, Ideker T (2007) Integrating physical and genetic maps: from genomes to interaction networks. Nat Rev Genet 8:699–710

    Article  Google Scholar 

  7. Bignell GR, Greenman CD, Davies H, Butler AP, Edkins S, Andrews JM, Buck G, Chen L, Beare D, Latimer C et al (2010) Signatures of mutation and selection in the cancer genome. Nature 463:893–898

    Article  Google Scholar 

  8. Bozic I, Antal T, Ohtsuki H, Carter H, Kim D, Chen S, Karchin R, Kinzler KW, Vogelstein B, Nowak MA (2010) Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci U S A 107:18545–18550

    Article  Google Scholar 

  9. Bradshaw-Pierce EL, Eckhardt SG, Gustafson DL (2007) A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Clin Cancer Res Off J Am Assoc Cancer Res 13:2768–2776

    Article  Google Scholar 

  10. Chin L, Gray JW (2008) Translating insights from the cancer genome into clinical practice. Nature 452:553–563

    Article  Google Scholar 

  11. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H et al (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Eng J Med 363:1734–1739

    Article  Google Scholar 

  12. Cohen A (2008) Pharmacokinetic and pharmacodynamic data to be derived from early-phase drug development: designing informative human pharmacology studies. Clin Pharmacokinet 47:373–381

    Article  Google Scholar 

  13. Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh CL, Feinberg AP (2002) Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res 62:6442–6446

    Google Scholar 

  14. D’Haeseleer P (2005) How does gene expression clustering work? Nat Biotechnol 23:1499–1501

    Article  Google Scholar 

  15. Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247:824–830

    Article  Google Scholar 

  16. Deisboeck TS, Zhang L, Martin S (2007) Advancing cancer systems biology: introducing the center for the development of a virtual tumor, CViT. Cancer Inform 5:1–8

    Google Scholar 

  17. Dobrin R, Zhu J, Molony C, Argman C, Parrish ML, Carlson S, Allan MF, Pomp D, Schadt EE (2009) Multi-tissue coexpression networks reveal unexpected subnetworks associated with disease. Genome Biol 10:R55

    Article  Google Scholar 

  18. Donelli MG, Rosso R, Garattini S (1967) Selective chemotherapy in relation to the site of tumor transplantation. Int J Cancer 2:421–424

    Article  Google Scholar 

  19. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Eng J Med 344:1031–1037

    Article  Google Scholar 

  20. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95:14863–14868

    Article  Google Scholar 

  21. Eissing T, Kuepfer L, Becker C, Block M, Coboeken K, Gaub T, Goerlitz L, Jaeger J, Loosen R, Ludewig B et al (2011) A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks. Front Physiol 2:4

    Article  Google Scholar 

  22. Fernandez AF, Assenov Y, Martin-Subero JI, Balint B, Siebert R, Taniguchi H, Yamamoto H, Hidalgo M, Tan AC, Galm O et al (2011) A DNA methylation fingerprint of 1628 human samples. Genome Res 22(2):407–419

    Article  Google Scholar 

  23. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O’Dwyer PJ, Lee RJ, Grippo JF, Nolop K et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Eng J Med 363:809–819

    Article  Google Scholar 

  24. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A et al (2011) COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res 39:D945–D950

    Article  Google Scholar 

  25. Gabrielsson J, Green AR (2009) Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology. J Pharmacol Exp Ther 331:767–774

    Article  Google Scholar 

  26. Gabrielsson J, Green AR, Van der Graaf PH (2010) Optimising in vivo pharmacology studies—practical PKPD considerations. J Pharmacol Toxicol Methods 61:146–156

    Article  Google Scholar 

  27. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA et al (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286:531–537

    Article  Google Scholar 

  28. Goteti K, Garner CE, Utley L, Dai J, Ashwell S, Moustakas DT, Gonen M, Schwartz GK, Kern SE, Zabludoff S et al (2010) Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents. Cancer Chemother Pharmacol 66:245–254

    Article  Google Scholar 

  29. Grabe N, Neuber K (2005) A multicellular systems biology model predicts epidermal morphology, kinetics and Ca2+ flow. Bioinformatics 21:3541–3547

    Article  Google Scholar 

  30. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C et al (2007) Patterns of somatic mutation in human cancer genomes. Nature 446:153–158

    Article  Google Scholar 

  31. Gutierrez ME, Kummar S, Giaccone G (2009) Next generation oncology drug development: opportunities and challenges. Nat Rev Clin Oncol 6:259–265

    Article  Google Scholar 

  32. Haber DA, Settleman J (2007) Cancer: drivers and passengers. Nature 446:145–146

    Article  Google Scholar 

  33. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70

    Article  Google Scholar 

  34. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674

    Article  Google Scholar 

  35. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J (1990) Acute leukaemia in bcr/abl transgenic mice. Nature 344:251–253

    Article  Google Scholar 

  36. Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Eng J Med 349:2042–2054

    Article  Google Scholar 

  37. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, Manolio TA (2009) Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A 106:9362–9367

    Article  Google Scholar 

  38. Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabe RR, Bhan MK, Calvo F, Eerola I, Gerhard DS et al (2010) International network of cancer genome projects. Nature 464:993–998

    Article  Google Scholar 

  39. Iadevaia S, Lu Y, Morales FC, Mills GB, Ram PT (2010) Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res 70:6704–6714

    Article  Google Scholar 

  40. Ideker T (2004) Systems biology 101—what you need to know. Nat Biotechnol 22:473–475

    Article  Google Scholar 

  41. Ideker T, Lauffenburger D (2003) Building with a scaffold: emerging strategies for high- to low-level cellular modeling. Trends Biotechnol 21:255–262

    Article  Google Scholar 

  42. Iyengar R, Zhao S, Chung SW, Mager DE, Gallo JM (2012) Merging systems biology with pharmacodynamics. Sci Transl Med 4(126):126ps7

    Article  Google Scholar 

  43. Jones HM, Gardner IB, Watson KJ (2009) Modelling and PBPK simulation in drug discovery. AAPS J 11:155–166

    Article  Google Scholar 

  44. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–428

    Article  Google Scholar 

  45. Kingsford C, Salzberg SL (2008) What are decision trees? Nat Biotechnol 26:1011–1013

    Article  Google Scholar 

  46. Krogh A (2008) What are artificial neural networks? Nat Biotechnol 26:195–197

    Article  Google Scholar 

  47. Kummar S, Gutierrez M, Doroshow JH, Murgo AJ (2006) Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol 62:15–26

    Article  Google Scholar 

  48. Langley RR, Ramirez KM, Tsan RZ, Van Arsdall M, Nilsson MB, Fidler IJ (2003) Tissue-specific microvascular endothelial cell lines from H-2K(b)-tsA58 mice for studies of angiogenesis and metastasis. Cancer Res 63:2971–2976

    Google Scholar 

  49. Lugo TG, Pendergast AM, Muller AJ, Witte ON (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247:1079–1082

    Article  Google Scholar 

  50. Luo J, Solimini NL, Elledge SJ (2009) Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136:823–837

    Article  Google Scholar 

  51. Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6:583–592

    Article  Google Scholar 

  52. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E et al (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267–273

    Article  Google Scholar 

  53. Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, Street SD (2011) Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today 17(9–10):419–424

    Google Scholar 

  54. Nakajima M, Welch DR, Belloni PN, Nicolson GL (1987) Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. Cancer Res 47:4869–4876

    Google Scholar 

  55. Noble WS (2006) What is a support vector machine? Nat Biotechnol 24:1565–1567

    Article  Google Scholar 

  56. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D et al (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324:1457–1461

    Article  Google Scholar 

  57. Orton RJ, Adriaens ME, Gormand A, Sturm OE, Kolch W, Gilbert DR (2009) Computational modelling of cancerous mutations in the EGFR/ERK signalling pathway. BMC Syst Biol 3:100

    Article  Google Scholar 

  58. Overall CM, Wrana JL, Sodek J (1989) Independent regulation of collagenase, 72-kDa progelatinase, and metalloendoproteinase inhibitor expression in human fibroblasts by transforming growth factor-beta. J Biol Chem 264:1860–1869

    Google Scholar 

  59. Park ES, Kim SJ, Kim SW, Yoon SL, Leem SH, Kim SB, Kim SM, Park YY, Cheong JH, Woo HG et al (2011) Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis. Proc Natl Acad Sci U S A 108:17456–17461

    Article  Google Scholar 

  60. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W (2001) Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286:2270–2279

    Article  Google Scholar 

  61. Pinkel D, Albertson DG (2005) Array comparative genomic hybridization and its applications in cancer. Nat Genet 37(Suppl):S11–S17

    Article  Google Scholar 

  62. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Barrette TR, Ghosh D, Chinnaiyan AM (2005) Mining for regulatory programs in the cancer transcriptome. Nat Genet 37:579–583

    Article  Google Scholar 

  63. Ringner M (2008) What is principal component analysis? Nat Biotechnol 26:303–304

    Article  Google Scholar 

  64. Rosenbaum E, Hoque MO, Cohen Y, Zahurak M, Eisenberger MA, Epstein JI, Partin AW, Sidransky D (2005) Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res Off J Am Assoc Cancer Res 11:8321–8325

    Article  Google Scholar 

  65. Rowley JD (1973) Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290–293

    Article  Google Scholar 

  66. Rual JF, Venkatesan K, Hao T, Hirozane-Kishikawa T, Dricot A, Li N, Berriz GF, Gibbons FD, Dreze M, Ayivi-Guedehoussou N et al (2005) Towards a proteome-scale map of the human protein–protein interaction network. Nature 437:1173–1178

    Article  Google Scholar 

  67. Salphati L, Pang J, Plise EG, Lee LB, Olivero AG, Prior WW, Sampath D, Wong S, Zhang X (2012) Preclinical assessment of the absorption and disposition of the PI3K/mTOR inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human. Drug Metab Dispos 40(9):1785–96

    Google Scholar 

  68. Segal E, Friedman N, Kaminski N, Regev A, Koller D (2005) From signatures to models: understanding cancer using microarrays. Nat Genet 37(Suppl):S38–S45

    Article  Google Scholar 

  69. Segal E, Shapira M, Regev A, Pe’er D, Botstein D, Koller D, Friedman N (2003) Module networks: identifying regulatory modules and their condition-specific regulators from gene expression data. Nat Genet 34:166–176

    Article  Google Scholar 

  70. Shen L, Kondo Y, Ahmed S, Boumber Y, Konishi K, Guo Y, Chen X, Vilaythong JN, Issa JP (2007) Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Cancer Res 67:11335–11343

    Article  Google Scholar 

  71. Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, Germani M, Poggesi I, Rocchetti M (2004) Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 64:1094–1101

    Article  Google Scholar 

  72. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N et al (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314:268–274

    Article  Google Scholar 

  73. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561–566

    Article  Google Scholar 

  74. Sorger PK, Allerheiligen SRB, Abernethy DR, Altman KL, Brouwer R, Califano A, D’Argenio DZ, Iyengar R, Jusko WJ, Lalonde R et al (2011) Quantitative and systems pharmacology in the post-genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms. In: Ward R (ed) An NIH White Paper by the QSP Workshop Group—October 2011

    Google Scholar 

  75. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869–10874

    Article  Google Scholar 

  76. Stelzl U, Worm U, Lalowski M, Haenig C, Brembeck FH, Goehler H, Stroedicke M, Zenkner M, Schoenherr A, Koeppen S et al (2005) A human protein-protein interaction network: a resource for annotating the proteome. Cell 122:957–968

    Article  Google Scholar 

  77. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence M, Sougnez C, McKenna A et al (2011) The mutational landscape of head and neck squamous cell carcinoma. Science 333(6046):1157–1160

    Article  Google Scholar 

  78. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102:15545–15550

    Article  Google Scholar 

  79. Sun W, Pierce E, Vicini P (2011) Development of a physiologically-based pharmacokinetic (PBPK) model of Vandetanib. AAPS J 13:R6353

    Google Scholar 

  80. Tan AC, Jimeno A, Lin SH, Wheelhouse J, Chan F, Solomon A, Rajeshkumar NV, Rubio-Viqueira B, Hidalgo M (2009) Characterizing DNA methylation patterns in pancreatic cancer genome. Mol Oncol 3:425–438

    Article  Google Scholar 

  81. TCGA (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061–1068

    Article  Google Scholar 

  82. TCGA (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474:609–615

    Article  Google Scholar 

  83. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R et al (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644–648

    Article  Google Scholar 

  84. Tredan O, Galmarini CM, Patel K, Tannock IF (2007) Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99:1441–1454

    Article  Google Scholar 

  85. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98:5116–5121

    Article  MATH  Google Scholar 

  86. van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536

    Article  Google Scholar 

  87. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse HL, Roberts C, Marton MJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Eng J Med 347:1999–2009

    Article  Google Scholar 

  88. van der Graaf PH, Benson N (2011) Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharm Res 28:1460–1464

    Article  Google Scholar 

  89. von Kriegsheim A, Baiocchi D, Birtwistle M, Sumpton D, Bienvenut W, Morrice N, Yamada K, Lamond A, Kalna G, Orton R et al (2009) Cell fate decisions are specified by the dynamic ERK interactome. Nat Cell Biol 11:1458–1464

    Article  Google Scholar 

  90. Weinstein IB (2002) Cancer. Addiction to oncogenes—the Achilles heal of cancer. Science 297:63–64

    Article  Google Scholar 

  91. Wiest T, Schwarz E, Enders C, Flechtenmacher C, Bosch FX (2002) Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 21:1510–1517

    Article  Google Scholar 

  92. Wilmanns C, Fan D, O'Brian CA, Bucana CD, Fidler IJ (1992) Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. Int J Cancer 52:98–104

    Article  Google Scholar 

  93. Wong H, Choo EF, Alicke B, Ding X, La H, McNamara E, Theil FP, Tibbitts J, Friedman LS, Hop CE et al (2012) Anti-tumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin Cancer Res Off J Am Assoc Cancer Res 18(14):3846–3855

    Article  Google Scholar 

  94. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J et al (2007) The genomic landscapes of human breast and colorectal cancers. Science 318:1108–1113

    Article  Google Scholar 

  95. Workman P, Aboagye EO, Chung YL, Griffiths JR, Hart R, Leach MO, Maxwell RJ, McSheehy PM, Price PM, Zweit J (2006) Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst 98:580–598

    Article  Google Scholar 

  96. WTCCC (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447:661–678

    Article  Google Scholar 

  97. Wu FT, Stefanini MO, Mac Gabhann F, Popel AS (2009) Modeling of growth factor-receptor systems from molecular-level protein interaction networks to whole-body compartment models. Methods Enzymol 467:461–497

    Article  Google Scholar 

  98. Yamazaki S, Nguyen L, Vekich S, Shen Z, Yin MJ, Mehta PP, Kung PP, Vicini P (2011) Pharmacokinetic–pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available heat shock protein 90 inhibitor in a human tumor xenograft mouse model. J Pharmacol Exp Ther 338:964–973

    Article  Google Scholar 

  99. Yamazaki S, Skaptason J, Romero D, Lee JH, Zou HY, Christensen JG, Koup JR, Smith BJ, Koudriakova T (2008) Pharmacokinetic–pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab Dispos Biol Fate Chem 36:1267–1274

    Article  Google Scholar 

  100. Yap TA, Sandhu SK, Workman P, de Bono JS (2010) Envisioning the future of early anticancer drug development. Nat Rev Cancer 10:514–523

    Article  Google Scholar 

  101. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG (2004) Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64:1975–1986

    Article  Google Scholar 

  102. Yeung KY, Ruzzo WL (2001) Principal component analysis for clustering gene expression data. Bioinformatics 17:763–774

    Article  Google Scholar 

  103. Yu H, Tardivo L, Tam S, Weiner E, Gebreab F, Fan C, Svrzikapa N, Hirozane-Kishikawa T, Rietman E, Yang X et al (2011) Next-generation sequencing to generate interactome datasets. Nat Methods 8:478–480

    Article  Google Scholar 

  104. Zhou Q, Gallo JM (2011) The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic. AAPS J 13:111–120

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Science, Skaggs School of Pharmacy, University of Colorado Anschutz Medical Campus, C238, 12850 E. Montview Blvd., Rm 4107, Aurora, CO, 80045, USA

    Erica L. Bradshaw Pierce

  2. University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA

    Erica L. Bradshaw Pierce & Aik Choon Tan

  3. Division of Medical Oncology, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, 8117, 12801 E. 17th Avenue, RC1S-Rm8103, Aurora, CO, 80045, USA

    Aik Choon Tan

  4. Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA

    Aik Choon Tan

Authors
  1. Erica L. Bradshaw Pierce
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aik Choon Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aik Choon Tan .

Editor information

Editors and Affiliations

  1. , School of Engineering & Design, Brunel University, London, UB8 3PH, United Kingdom

    Michael W. Collins

  2. , Brunel Institute for Bioengineering, Brunel University, London, UB8 3PH, United Kingdom

    Carola S. Koenig

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Pierce, E.L.B., Tan, A.C. (2013). Integrating “Omics” Data for Quantitative and Systems Pharmacology in Translational Oncology. In: Collins, M., Koenig, C. (eds) Micro and Nano Flow Systems for Bioanalysis. Bioanalysis, vol 2. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-4376-6_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-4376-6_12

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-4375-9

  • Online ISBN: 978-1-4614-4376-6

  • eBook Packages: Physics and AstronomyPhysics and Astronomy (R0)

Publish with us

Policies and ethics

Search

Navigation